RxDoctor Payments Data

Andrew Metz, DO

Family Medicine · Deer Park, TXNPI 1912035189

Payments from drug & device makers

$521in general payments, 2019–2025

Across 24 payments — averaging $21.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$138
  • Smith+Nephew$100
  • GSK$50
  • Dynavax Technologies Corporation$31
  • Boehringer Ingelheim$28
  • Intuitive Surgical$26
  • plus $148 from 8 others

What the payments were for

  • Food & beverage$521100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$521 in reported general payments places this provider in the 50th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$53,963
Medicare patients
171
Services billed
1,912

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide85$86,146
JardianceEmpagliflozin29$31,581
OzempicSemaglutide26$29,473
FarxigaDapagliflozin Propanediol21$22,897
JanuviaSitagliptin Phosphate24$22,362
EliquisApixaban15$18,597
TradjentaLinagliptin17$15,196
Tresiba Flextouch U-200Insulin Degludec13$9,702
Levothyroxine Sodium168$2,371
Atorvastatin Calcium175$1,471
SynthroidLevothyroxine Sodium15$1,395
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide41$1,306
Rosuvastatin Calcium127$1,246
Losartan Potassium107$1,172
Albuterol Sulfate HfaAlbuterol Sulfate27$1,143

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$28$46,77746 claims
Novo NordiskOzempic$15$29,47326 claims
AstraZenecaFarxiga$17$22,89721 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Deer Park

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →